This contributes to the debate of whether discontinuation of RAAS inhibitors and considering alternative antihypertensive therapy in times of COVID-19 would be a good practice or not.56 A marginal association of current use of ACE inhibitors with COVID-19-related death suggests that any increased risk of mortality is likely to be small and will need to be scrutinised in future as more data accumulate. Here, ACE is linked to COVID-19.